Background
The ongoing US HIV epidemic highlights the need for innovative strategies to promote pre-exposure prophylaxis (PrEP) uptake and reduce HIV incidence. Community pharmacy-based PrEP provides opportunity to expand access to this highly effective preventative therapy. Our study evaluated the potential health impacts, economic costs, and cost-effectiveness of community pharmacy-based PrEP for men who have sex with men (MSM) in the Atlanta metropolitan area, which has one of the highest burdens of HIV in the US.
Methods
We adapted a calibrated and validated dynamic transmission compartmental model to simulate a hypothetical policy change permitting community pharmacists to initiate PrEP for eligible MSM in Atlanta. We compared the addition of community pharmacy-based PrEP to the status quo (traditional clinic-based), assuming 50% increase in PrEP uptake over 2 years. We conducted scenario analyses with varying assumptions related to PrEP adherence, persistence, and telehealth delivery based on early studies of pharmacy-based PrEP and other related, established pharmacy-based services. Using a healthcare sector perspective we projected the costs (2023 US dollars) and outcomes of (HIV cases averted, quality-adjusted life-years [QALY]) over a 50-year time horizon. One-way and probabilistic sensitivity analyses with 2,000 parameter sets were used to characterize model uncertainty.
Results
We projected 34,670 new HIV cases and 89.5 million QALYs, at a cost of $423.8 billion, in the Atlanta metropolitan area under our status quo scenario. The addition of community pharmacy-based PrEP has the potential to reduce HIV incidence by 13.5%, increase QALYs by 0.2%, and decrease costs by 0.02% over the 50-year time horizon. Our scenario analyses consistently found pharmacy-based PrEP to result in improved health outcomes and either cost-saving or cost-effective compared to the status quo.
Conclusions
A policy permitting community pharmacies to provide PrEP services could lead to substantial clinical benefits and cost savings in Atlanta. However, additional research is needed to address challenges in scale-up, ensure financial sustainability, and realize the full potential of pharmacy-based PrEP interventions. Our study offers valuable insights for policymakers to improve access to HIV PrEP and work towards ending the HIV epidemic in the US.